The use of B-type natriuretic peptide in the management of elderly patients with acute dyspnoea

Journal of Internal Medicine

Volumn 258, Issue 1, 2005, Pages 77-85

  Mueller, Christian ^a   Laule Kilian, K ^a   Frana, B ^a   Rodriguez, D ^a   Rudez, J ^a   Scholer, A ^a   Buser, P ^a   Pfisterer, M ^a   Perruchoud, A P ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Dyspnoea; Elderly patients; Emergency diagnosis; Natriuretic peptides

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DYSPNEA; ELDERLY CARE; FEMALE; HEART FAILURE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; RISK ASSESSMENT;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; CARDIAC OUTPUT, LOW; DYSPNEA; FEMALE; HOSPITALIZATION; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PNEUMONIA; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 21344472629     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01503.x     Document Type: Article

References (25)

1. Redfield MM. Heart failure - an epidemic of uncertain proportions. N Engl J Med 2002; 347: 1442-4.
2. Havranek EP, Masoudi FA, Westfall KA et al. Spectrum of heart failure in older patients: results from the national heart failure project. Am Heart J 2002; 143: 412-7.
3. Gottdiener JS, McClelland RL, Marshall R et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. Ann Intern Med 2002; 137: 631-9.
4. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. Dallas. TX: American Heart Association, 2002.
5. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2001; 104: 2996-3007.
6. Remme WJ, Swedberg K; Task force for the diagnosis and treatment of chronic heart failure. European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60.
7. Bales AC, Sorrentino MJ. Causes of congestive heart failure: prompt diagnosis may affect prognosis. Postgrad Med 1997; 101: 54-6.
8. Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med 1992; 21: 669-74.
9. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-7.
10. Maisel AS, Clopton P, Krishnaswamy P et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from Breathing Not Properly (BNP) Multinational Study. Am Heart J 2004; 147: 1078-84.
11. McDonagh TA, Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
12. Davis M, Espiner E, Richards G et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 1994; 343: 440-4.
13. Maisel AS, Koon J, Krishnaswamy P. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141: 367-74.
14. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40: 976-82.
15. Wang TJ, Larson MG, Levy D et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90: 254-8.
16. TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 2001; 358: 951-7.
17. Pfisterer M, Buser P, Osswald S et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 2003; 289: 1117-23.
18. Pfisterer M. for the TIME Investigators. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy. Four-year follow-up of the randomized Trial of Invasive Versus Medical Therapy in Elderly Patients (TIME). Circulation 2004; 110: 1213-8.
19. Mueller C, Scholer A, Laule Kilian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647-54.
20. Cheng V, Kazanagra R, Garcia A et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37: 386-91.
21. Mueller C, Buser P. B-type natriuretic peptide (BNP): can it improve our management of patients with congestive heart failure? Swiss Med Wkly 2002; 132: 618-22.
22. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-8.
23. Siegel JE, Weinstein MC, Russell LB, Gold MR, for the Panel on Cost-Effectiveness in Heath and Medicine. Recommendations for reporting cost-effectiveness analysis. JAMA 1996; 276: 1339-41.
24. McCullough PA, Duc P, Omland T et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the breathing not properly multinational study. Am J Kidney Dis 2003; 41: 571-9.
25. Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109: 594-600.